Inactive Instrument

Press Releases Kadimastem Ltd TEL AVIV STOCK EXCHANGE

Equities

IL0011284614

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

IMC announces the termination of a preliminary term sheet with Kadimastem Ltd., a public company traded on the Tel Aviv Stock Exchange to fully focus on the recently legalized German market	05-28	AQ
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC	02-28	AQ
IMC Announces Potential Reverse Merger with Kadimastem a leading Clinical cell therapy company	02-28	AQ
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq	02-16	AQ
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India	02-07	AQ
A peer reviewed article on Kadimastem's AstroRxÃ‚® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology	01-25	AQ
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA	01-22	AQ
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes	11-07	AQ
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes	23-06-20	AQ
Kadimastem : Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS	21-03-09	PR
Kadimastem : Announces Executive Management Changes	21-02-01	PR
Kadimastem : AstroRx® shows promise in early phase amyotrophic lateral sclerosis trial	20-12-16	AQ
Kadimastem : Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS	20-08-03	PR
Kadimastem : Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS	20-01-06	PR
Kadimastem : Announces the Completion of Treatment for Cohort B of Its Phase 1/2a Clinical Trial in ALS Patients	19-12-23	PR
Kadimastem : Intends to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol Following Recent Positive Interim Results	19-11-18	PR
Kadimastem : to Present Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in Tel-Aviv, Israel	19-11-11	PR
Kadimastem : Announces Promising Interim Results of Cohort A of Its Phase 1/2a Clinical Trial in ALS	19-09-24	PR
Kadimastem : Announces Leadership Changes	19-05-29	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer